Selected research
Industry Research
Orphan Drug Development Industry Research Report 2026
Market perspective
The global Orphan Drug Development market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Orphan Drug Development market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Orphan Drug Development market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Orphan Drug Development market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Orphan Drug Development include Novartis, Roche, Celgene, BMS, Shire, Merck, J&J, Pfizer and Biogen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Orphan Drug Development market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Orphan Drug Development.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Orphan Drug Development Market by Company
Novartis
Roche
Celgene
BMS
Shire
Merck
J&J
Pfizer
Biogen
Sanofi
AstraZeneca
Takeda
Orphan Drug Development Segment by Type
Pediatric Orphan Drugs
Adult Orphan Drugs
Orphan Drug Development Segment by Application
Congenital and Genetic Diseases
Tumors and Cancer
Endocrine Diseases
Others
Orphan Drug Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Orphan Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drug Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Orphan Drug Development companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pediatric Orphan Drugs
- Adult Orphan Drugs
Applications
- Congenital and Genetic Diseases
- Tumors and Cancer
- Endocrine Diseases
- Others
Companies covered
- Novartis
- Roche
- Celgene
- BMS
- Shire
- Merck
- J&J
- Pfizer
- Biogen
- Sanofi
- AstraZeneca
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Orphan Drug Development by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pediatric Orphan Drugs
- 2.2.3 Adult Orphan Drugs
- 2.3 Orphan Drug Development by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Congenital and Genetic Diseases
- 2.3.3 Tumors and Cancer
- 2.3.4 Endocrine Diseases
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Orphan Drug Development Breakdown Data by Type
- 3.1 Global Orphan Drug Development Historic Market Size by Type (2021-2026)
- 3.2 Global Orphan Drug Development Forecasted Market Size by Type (2027-2032)
4 Orphan Drug Development Breakdown Data by Application
- 4.1 Global Orphan Drug Development Historic Market Size by Application (2021-2026)
- 4.2 Global Orphan Drug Development Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Orphan Drug Development Market Perspective (2021-2032)
- 5.2 Global Orphan Drug Development Growth Trends by Region
- 5.2.1 Global Orphan Drug Development Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Orphan Drug Development Historic Market Size by Region (2021-2026)
- 5.2.3 Orphan Drug Development Forecasted Market Size by Region (2027-2032)
- 5.3 Orphan Drug Development Market Dynamics
- 5.3.1 Orphan Drug Development Industry Trends
- 5.3.2 Orphan Drug Development Market Drivers
- 5.3.3 Orphan Drug Development Market Challenges
- 5.3.4 Orphan Drug Development Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Orphan Drug Development Players by Revenue
- 6.1.1 Global Top Orphan Drug Development Players by Revenue (2021-2026)
- 6.1.2 Global Orphan Drug Development Revenue Market Share by Players (2021-2026)
- 6.2 Global Orphan Drug Development Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Orphan Drug Development Head Office and Area Served
- 6.4 Global Orphan Drug Development Players, Product Type & Application
- 6.5 Global Orphan Drug Development Manufacturers Established Date
- 6.6 Global Orphan Drug Development Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Orphan Drug Development Market Size (2021-2032)
- 7.2 North America Orphan Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Orphan Drug Development Market Size by Country (2021-2026)
- 7.4 North America Orphan Drug Development Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Orphan Drug Development Market Size (2021-2032)
- 8.2 Europe Orphan Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Orphan Drug Development Market Size by Country (2021-2026)
- 8.4 Europe Orphan Drug Development Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Orphan Drug Development Market Size (2021-2032)
- 9.2 Asia-Pacific Orphan Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Orphan Drug Development Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Orphan Drug Development Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Orphan Drug Development Market Size (2021-2032)
- 10.2 South America Orphan Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Orphan Drug Development Market Size by Country (2021-2026)
- 10.4 South America Orphan Drug Development Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Orphan Drug Development Market Size (2021-2032)
- 11.2 Middle East & Africa Orphan Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Orphan Drug Development Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Orphan Drug Development Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Orphan Drug Development Business (2021-2026)
- 12.1.4 Novartis Orphan Drug Development Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Orphan Drug Development Business (2021-2026)
- 12.2.4 Roche Orphan Drug Development Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Celgene
- 12.3.1 Celgene Company Information
- 12.3.2 Celgene Business Overview
- 12.3.3 Celgene Revenue in Orphan Drug Development Business (2021-2026)
- 12.3.4 Celgene Orphan Drug Development Product Portfolio
- 12.3.5 Celgene Recent Developments
- 12.4 BMS
- 12.4.1 BMS Company Information
- 12.4.2 BMS Business Overview
- 12.4.3 BMS Revenue in Orphan Drug Development Business (2021-2026)
- 12.4.4 BMS Orphan Drug Development Product Portfolio
- 12.4.5 BMS Recent Developments
- 12.5 Shire
- 12.5.1 Shire Company Information
- 12.5.2 Shire Business Overview
- 12.5.3 Shire Revenue in Orphan Drug Development Business (2021-2026)
- 12.5.4 Shire Orphan Drug Development Product Portfolio
- 12.5.5 Shire Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Orphan Drug Development Business (2021-2026)
- 12.6.4 Merck Orphan Drug Development Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 J&J
- 12.7.1 J&J Company Information
- 12.7.2 J&J Business Overview
- 12.7.3 J&J Revenue in Orphan Drug Development Business (2021-2026)
- 12.7.4 J&J Orphan Drug Development Product Portfolio
- 12.7.5 J&J Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Orphan Drug Development Business (2021-2026)
- 12.8.4 Pfizer Orphan Drug Development Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Biogen
- 12.9.1 Biogen Company Information
- 12.9.2 Biogen Business Overview
- 12.9.3 Biogen Revenue in Orphan Drug Development Business (2021-2026)
- 12.9.4 Biogen Orphan Drug Development Product Portfolio
- 12.9.5 Biogen Recent Developments
- 12.10 Sanofi
- 12.10.1 Sanofi Company Information
- 12.10.2 Sanofi Business Overview
- 12.10.3 Sanofi Revenue in Orphan Drug Development Business (2021-2026)
- 12.10.4 Sanofi Orphan Drug Development Product Portfolio
- 12.10.5 Sanofi Recent Developments
- 12.11 AstraZeneca
- 12.11.1 AstraZeneca Company Information
- 12.11.2 AstraZeneca Business Overview
- 12.11.3 AstraZeneca Revenue in Orphan Drug Development Business (2021-2026)
- 12.11.4 AstraZeneca Orphan Drug Development Product Portfolio
- 12.11.5 AstraZeneca Recent Developments
- 12.12 Takeda
- 12.12.1 Takeda Company Information
- 12.12.2 Takeda Business Overview
- 12.12.3 Takeda Revenue in Orphan Drug Development Business (2021-2026)
- 12.12.4 Takeda Orphan Drug Development Product Portfolio
- 12.12.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst